Home » FDA Approves New Indication for GSK's Arixtra
FDA Approves New Indication for GSK's Arixtra
GlaxoSmithKline's (GSK) antithrombotic drug Arixtra has been approved by the FDA for use in patients undergoing abdominal surgery.
Under GSK's supplemental new drug application, Arixtra (fondaparinux sodium) is now indicated for the prevention of venous thromboembolism (VTE) in patients undergoing abdominal surgery who are at risk of thromboembolic complications. Up to 2 million cases of VTE occur in the U.S. each year, the company said.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct